ANALYSIS, NOT A POSITION - AND THE LARGEST REVERSAL IN THE BATCH. Both BINDING Criteria now PASS. The old binding gate (Gate 2, variant vs consensus) is DISSOLVED by the current framework, and the old Gate 4 failure (E[R] +0.64% against a 4.7% cash hurdle, short by 4.06pp) rested on a hurdle that no longer exists. Quality Criteria PASS on all three INFLECTION limbs: 70.4% TTM gross margin, +36.2pp operating-margin expansion, +103.4% demonstrated revenue CAGR. Valuation Criteria PASS: the $5,690m enterprise value requires a 50.3% CAGR against 103.4% demonstrated - a margin of +53.1pp - at a GROWTH_MATCHED 33.0x exit multiple (n=7, a thin anchor) implying 124.3 turns of compression from 157.3x. The flip point is 12.0x, roughly a third of the anchor. A 4.1x SHARE-COUNT ERROR had to be corrected first: the scan used 11,178,467, the pre-IPO Class A count at 2025-09-30, against the verified 45,995,484 (Class A+B, 10-Q cover 2026-05-04) - the EntityPublicFloat sanity floor could not fire because BLLN publishes no such tag. The old scan record would have returned a confident PASS for the wrong reason. 12-month target $152, +13.8% to spot, anchored on BLLN's own 12.3x median EV/Sales against a current 18.6x at the 100th percentile of its own history - the target is above spot because NTM revenue growth outruns that multiple compression. Qualifier stated with the PASS: 8.5% of Q1'26 revenue was a $9.2m prior-period true-up, confirmed verbatim in the 10-Q; ex that item Q1 growth is +68.2% rather than +83.8%. Momentum 12-1 is INDETERMINATE, not zero - only ~180 sessions since the 2025-11-06 IPO.
How to read this
This is an analysis, not a position. The memo scores every Criteria and blocks on none of them. Whether an analysis justifies a position is a question about a particular book, and two books answer it differently — so this page carries no Long, Short, Watchlist or Avoid verdict. The previous verdict has been retired.
Every Criteria returns PASS / FAIL / INDETERMINATE, and carries a type. BINDING criteria are admission tests for a long-only absolute-return strategy. MEASURED criteria are always scored and stored, and never block — they inform timing, sizing or a future strategy. A missing input is INDETERMINATE, never FAIL.
Two valuation outputs, over two horizons. The implied-path test (reverse DCF) asks what today's price requires over five years and whether the business has demonstrated it; the 12-month target asks what the name is likely to trade at, on near-term consensus and the name's own multiple history. Neither replaces the other. Sensitivity is run over the exit multiple, never over scenario probabilities.
Momentum is entry timing only. It governs when to enter a position the thesis already justifies, never whether to own one.
Key findings
- IDENTITY: BLLN resolves to BillionToOne, Inc. (CIK 0002070849), a Nasdaq-listed molecular diagnostics company - NOT Ballard Power [BLDP] and NOT Bloom Energy [BE]. Both near-matches were explicitly checked and rejected against the SEC ticker file.
- ORGANIC GROWTH DECELERATED FAR MORE THAN REPORTED GROWTH. The Q1-2026 10-Q discloses $9.2m of revenue from performance obligations satisfied in PRIOR periods - more than the $8.7m recognised across ALL of FY2025, and equal to 8.5% of the quarter. Ex-true-up, sequential growth was +5.4% versus the +12.8% headline, against +15% to +26% through 2025. The conclusion is robust across every plausible allocation of FY2025's true-up (+3.3% to +9.9%).
- THE PRICE REQUIRES AN ONCOLOGY COMPANY THAT DOES NOT YET EXIST. A reverse DCF at $133.64 requires ~$3,515m of FY2035 revenue - 11.5x FY2025, or ~5.9m billable tests a year against 610,000 delivered in FY2025. The bottom-up US prenatal SAM tops out near $735-850m, so oncology must become roughly three-quarters of the company. Oncology today is $10.7m a quarter with ONE PubMed publication for Northstar Select against 151 for Natera's Signatera, and ZERO registered MRD trials on ClinicalTrials.gov.
- THE HOUSE FORECAST IS ABOVE CONSENSUS AND THE NAME IS STILL REJECTED ON THE MULTIPLE - the fifth healthcare instance of calibration item B8. House FY2026 $462m vs consensus $454m (+1.8%); FY2027 +4.2%. Essentially none of the gap to the Street's $122.14 target is about the numbers.
- BUT BLLN PARTIALLY DISCRIMINATES B8, which is why it matters. Unlike TXG and TWST, whose Gate 4 flip points were unreachable at even a 0% bear weight, BLLN fails by only 4.06pp and its flip point is a 22% bear weight against the 30% used. The hurdle sits INSIDE the E[R] range. Earnings quality is also clean on every standard quantitative measure (accruals -1.14%, GP/TA 0.356, F-score 7/8) - so this is close to the clean-earnings-quality healthcare test case B8 was waiting for, with two caveats noted below.
- MATERIAL WEAKNESSES IN INTERNAL CONTROL REMAIN UNREMEDIATED per the FY2025 10-K - an under-resourced control environment with inadequate segregation of duties, controls over certain financial instruments, and IT general controls. Scoped honestly: they do NOT name revenue recognition, which limits the weight they can carry, but revenue here is unusually estimate-dependent and the true-up line is accelerating.
- TWO REAL MODEL BUGS WERE CAUGHT BY OPENING THE WORKBOOK IN EXCEL rather than trusting the formula strings. The DCF was discounting at 135% because the WACC reference pointed at the beta cell; and the ten-year forecast carried only nine years of cost percentages, leaving FY2035 with revenue but no expenses and inflating the Gordon terminal value from $4,297m to $17,960m - producing a 'fair value' of $147/share, above spot. Neither would have been caught by the balance check, which read 0.00 throughout.
- THE MEASURED BETA WAS REJECTED AND THE REASON MATTERS. The 180-session post-IPO beta of 1.75 decomposes as rho 0.272 x (85.3%/13.3%) - it is almost entirely idiosyncratic volatility, which CAPM does not compensate, over far too short a sample. A peer-informed 1.35 was used (WACC 11.45%). Using 1.75 uncritically would have printed ~$42 fair value and produced far more confidence than the evidence supports.
- DCF AND COMPS GENUINELY CONFLICT, AND THE MEMO DOES NOT RESOLVE IT BY PICKING THE CONVENIENT ONE. DCF base is $53.35 (Gordon) to $79.90 (4.5x exit) against spot $133.64 - yet at 10.8x EV/FY2027E sales BLLN is CHEAPER than NTRA (~11.9x) and GH (~14.4x) at roughly triple their growth, and sits below the peer growth-adjusted regression line.
- NOT A SHORT, AND THE NET CASE IS NAMED EXPLICITLY. The whole bear case is the multiple. The house forecast is above consensus, the factor scorecard is clean in every dimension a short would need to be dirty, and the stock closed at its all-time high on the memo date. Expensive is not a short.
- OPTIONS EXIST BUT ARE NOT USABLE AT SIZE - 232 contracts across four expiries, but only 1,585 contracts of chain volume and ATM bid/ask spreads of 16-32% of mid. Alpaca's impliedVolatility field was recomputed by Black-Scholes rather than trusted, and on THIS name it checked out to within ~0.01 vol points. ATM IV of 72.6-76.8% sits BELOW realised volatility of 79-85%, so premium is not overpriced here - the spreads destroy the edge, not the pricing.
- BLLN IS THE LEAST CORRELATED HEALTHCARE NAME IN COVERAGE. Maximum pairwise correlation to any coverage name is +0.356 (TWST); only +0.338 to Natera despite being a direct prenatal competitor, and +0.261 to Guardant. No pair approaches the book's 0.60 disclosure threshold.
- INSIDER ACTIVITY READ THROUGH THE CORRECT ASYMMETRY. All $3.18m of 'purchases' were at exactly $60.00 on 10-12 November 2025 - IPO participations, not opportunistic buys. All $21.62m of sales fall after the 2026-05-05 lock-up expiry and are treated as noise per Cohen, Malloy & Pomorski. The informative fact is the ABSENCE of clustered buying at market prices.
Sections
Disclosed limitations
- MENTION-FREQUENCY IS NOT YET INFORMATIVE ON THIS NAME. Only three quarters exist - the company's entire post-IPO history - versus the 8-quarter minimum and 12-16 target. Alpha Vantage was exhausted for the day; Motley Fool carries only the Q1-2026 call (Q3-25 and Q4-25 return HTTP 404), so a three-point transcript series from a single source could not be built. The series therefore uses EDGAR 8-K EX-99.1 earnings releases (one source, all three quarters, normalised per 10k words) and the Q1-2026 transcript is used separately and labelled for qualitative colour only. Apparent movements in the series are dominated by the product-launch news cycle and two are called out as artifacts rather than reported as findings.
- NO 12-1 MOMENTUM AND NO 200-DAY MOVING AVERAGE EXIST - only 180 trading sessions since the IPO. The momentum factors are reported on 52-week-high proximity and the 50-day mean instead, with the limitation stated rather than the rows silently omitted.
- THE QUARTERLY ALLOCATION OF FY2025'S $8.7m TRUE-UP IS AN ASSUMPTION. Only the FY2025 total and the Q1-25 figure ($2.9m) are disclosed; Q2-Q4 were assumed to split evenly. Sensitivity is shown: organic Q1-26 sequential growth ranges from +3.3% to +9.9% across allocations. The deceleration conclusion is robust; the precise number is not.
- CONSENSUS DEPTH IS THIN AND PARTLY PAYWALLED. Only 8 analysts cover the name. FY2027 and FY2028 consensus revenue sit behind a subscription on the source used, so the FY2027 consensus figure (~$590m) used in the Gate 2A comparison is an ESTIMATE, not a sourced number. Alpha Vantage EARNINGS_ESTIMATES was unavailable (daily quota exhausted at ~14:10 PDT by concurrent agents).
- INSTITUTIONAL OWNERSHIP IS A PARTIAL PULL. Three Schedule 13Gs and one 13D are on file, but EDGAR provides no single endpoint returning all holders of a ticker, so this is not a complete ownership picture.
- PEER CASH BALANCES COME FROM EDGAR XBRL AND NATERA'S TAG RETURNED A STALE 2022 DATE. Immaterial at a $36bn market cap, but flagged rather than silently used.
- SEVERAL TAM INPUTS ARE ESTIMATES, NOT SOURCED FIGURES - NIPT penetration of US pregnancies (~55-65%), the penetration ceiling (~80%), the mature blended ASP (~$600), and the addressable advanced-solid-tumour pool (600-700k). Ranges are shown rather than point estimates where the input could not be sourced.
- THE HOUSE BETA OF 1.35 IS AN ASSUMPTION, not a measured figure. The measured 1.75 was rejected for the reasons given, but 1.35 is a judgement anchored on peer diagnostics betas and the valuation is materially sensitive to it.
- THE FY2026 GUIDANCE FIGURES IN THE MOTLEY FOOL TRANSCRIPT DISAGREE WITH THE FILED 8-K ($445-465m and $425-445m in the transcript versus $450-465m and $430-445m in the EX-99.1). The filed document is treated as authoritative throughout; the discrepancy is recorded because the transcript also misstates Q1 prenatal revenue as $97.7m against the 10-Q's $96.525m.
- GATE 4 IS JUDGEMENT-DETERMINED, NOT ANALYSIS-DETERMINED. The 4.7% hurdle sits inside the -9.01% to +7.76% E[R] range and the verdict flips at a 22% bear weight versus the 30% used. This is reported as a range with flip points per framework item C4 rather than as a confident FAIL.
- NO OPTIONS RECOMMENDATION WAS MADE and therefore no entry was appended to trade_recommendations.jsonl. Gate 5 failed for options on bid/ask spreads, and the overall decision is Watchlist, so there is no specific contract to log.
- DELIVERABLES ARE UNCOMMITTED. The orchestrating agent instructed that no git add or git commit be run because concurrent agents are active in this repository, so the commit_sha above is HEAD at time of writing rather than a commit containing these files. See PENDING_BLLN.md at the project root.